Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients

Pediatric Blood and Cancer

Volumn 58, Issue 4, 2012, Pages 630-632

  Au, Wing Y ^a   Li, Chi Kong ^b   Lee, Vincent ^b   Yuen, Hui Leung ^c   Yau, Jeffrey ^c   Chan, Godfrey C F ^a   Ha, Shau yin ^a   Kwong, Yok lam ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Non HSCT; Oral arsenic; Pediatric APL

Indexed keywords

ARSENIC TRIOXIDE; CYTOSINE; FLUDARABINE; RETINOIC ACID;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; CHILD; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LONG TERM CARE; MAINTENANCE CHEMOTHERAPY; MONOTHERAPY; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REMISSION; SCHOOL CHILD; STEM CELL TRANSPLANTATION;

ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC AGENTS; ARSENICALS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; OXIDES; RECURRENCE; TIME FACTORS;

EID: 84863175984     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23306     Document Type: Article

References (16)

1. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113: 1875-1891.
2. Ortega JJ, Madero L, Martin G, et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: A multicenter study by the PETHEMA Group. J Clin Oncol 2005; 23: 7632-7640.
3. Gregory J, Feusner J. Acute promyelocytic leukemia in childhood. Curr Oncol Rep 2009; 11: 439-445.
4. Bally C, Fadlallah J, Leverger G, et al. Outcome of APL in young children and adolescents in two consecutive trials of the European APL Group (Abs). Blood 2010; 116: 507.
5. Testi AM, Biondi A, Lo Coco F, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005; 106: 447-453.
6. Fox E, Razzouk BI, Widemann BC, et al. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood 2008; 111: 566-573.
7. Dvorak CC, Agarwal R, Dahl GV, et al. Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia. Biol Blood Marrow Transplant 2008; 14: 824-830.
8. Au WY, Lie AK, Chim CS, et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Ann Oncol 2003; 14: 752-757.
9. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009; 27: 3650-3658.
10. Au WY, Kumana CR, Kou M, et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 2003; 102: 407-408.
11. Ebinger M, Schwarze CP, Feuchtinger T, et al. Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy. Pediatr Hematol Oncol 2011; 28: 334-337.
12. Kwong YL, Wong KF, Chan TK. Trisomy 8 in acute promyelocytic leukaemia: An interphase study by fluorescence in situ hybridization. Br J Haematol 1995; 90: 697-700.
13. van der Velden VH, van der Sluijs-Geling A, Gibson BE, et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010; 24: 1599-1606.
14. Kumana CR, Au WY, Lee NS, et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol 2002; 58: 521-526.
15. Au WY, Chim CS, Lie AK, et al. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 2002; 117: 130-132.
16. Siu CW, Au WY, Yung C, et al. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: Implications for long-term cardiac safety. Blood 2006; 108: 103-106.